GlaxoSmithkline Pharmaceuticals Ltd (GLAX)

BSE
Currency in INR
2,152.70
-51.70(-2.35%)
Delayed Data
GLAX Scorecard
Full Analysis
Significant return over the last week
Earnings results expected today
Fair Value
Day's Range
2,149.152,202.90
52 wk Range
1,816.733,073.87
Key Statistics
Edit
Bid/Ask
2,149.50 / 2,152.35
Prev. Close
2,204.4
Open
2,189
Day's Range
2,149.15-2,202.9
52 wk Range
1,816.73-3,073.87
Volume
2K
Average Volume (3m)
4.26K
1-Year Change
-6.94%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLAX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
2,914.50
Upside
+35.39%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

GlaxoSmithkline Pharmaceuticals Ltd Company Profile

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Employees
3211
Market
India

Compare GLAX to Peers and Sector

Metrics to compare
GLAX
Peers
Sector
Relationship
P/E Ratio
55.3x34.6x−0.6x
PEG Ratio
8.900.720.00
Price/Book
22.3x6.2x2.6x
Price / LTM Sales
10.5x5.4x3.1x
Upside (Analyst Target)
32.9%17.2%48.2%
Fair Value Upside
Unlock−4.6%8.0%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2,914.50
(+35.39% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 39.84
Dividend Yield
2.00%
Industry Median 0.70%
Annualised payout
44
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Oct 29, 2024
EPS / Forecast
14.80 / 10.00
Revenue / Forecast
10.11B / 10.11B
EPS Revisions
Last 90 days

People Also Watch

1,487.95
GLAD
-1.89%
999.60
JUBA
-0.04%
1,678.00
JBCH
+0.40%
220.70
PIRM
-2.54%
520.55
KALN
-3.49%

FAQ

What Is the GlaxoSmithkline Pharma (GLAX) Stock Price Today?

The GlaxoSmithkline Pharma stock price today is 2,152.70

What Stock Exchange Does GlaxoSmithkline Pharma Trade On?

GlaxoSmithkline Pharma is listed and trades on the BSE stock exchange.

What Is the Stock Symbol for GlaxoSmithkline Pharma?

The stock symbol for GlaxoSmithkline Pharma is "GLAX."

Does GlaxoSmithkline Pharma Pay Dividends? What’s The Current Dividend Yield?

The GlaxoSmithkline Pharmaceuticals Ltd dividend yield is 2.00%.

What Is the GlaxoSmithkline Pharma Market Cap?

As of today, GlaxoSmithkline Pharma market cap is 364.56B.

What is GlaxoSmithkline Pharma Earnings Per Share?

The GlaxoSmithkline Pharma EPS is 39.84.

What Is the Next GlaxoSmithkline Pharma Earnings Date?

GlaxoSmithkline Pharma will release its next earnings report on 09 Feb 2025.

From a Technical Analysis Perspective, Is GLAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.